Resectability of Pancreatic Cancer Is in the Eye of the Observer
- Fabio Giannone, MD
- Giovanni Capretti, MD
- Mohammed Abu Hilal, MD, PhD
- Ugo Boggi, MD
- Donata Campra, MD
- Carla Cappelli, MD
- Riccardo Casadei, MD
- Raffaele De Luca, MD
- Massimo Falconi, MD
- Gabriele Giannotti, MD
- Luca Gianotti, MD
- Roberto Girelli, MD
- Paola Gollini, MD
- Davide Ippolito, MD
- Giorgio Limerutti, MD
- Lorenzo Maganuco, MD
- Valeria Malagnino, MD
- Giuseppe Malleo, MD, PhD
- Mario Morone, MD
- Cristina Mosconi, MD
- Federica Mrakic, MD
- Diego Palumbo, MD
- Roberto Salvia, MD, PhD
- Salvatore Sgroi, MD
- Alessandro Zerbi, MD
- Gianpaolo Balzano, MD
DOIAbstract
Objectives:. To determine the reproducibility of the National Comprehensive Cancer Network (NCCN) resectability status classification for pancreatic cancer. Background:. The NCCN classification defines 3 resectability classes (resectable, borderline resectable, locally advanced), according to vascular invasion. It is used to recommend different approaches and stratify patients during clinical trials. Methods:. Prospective, multicenter, observational study (trial ID: NCT03673423). Main outcome measure was the interobserver agreement of tumor assignment to different resectability classes and quantification of vascular invasion degrees. Agreement was measured by Fleiss’ k (k = 1 perfect agreement; k = 0 agreement by chance). Sixty-nine compute...
Add to ORKG